Statil inhibits aldose reductase and exhibits anticancer activity; it is primarily used to study aldose reductase function in vitro. In breast cancer and lung cancer cells, statil inhibits cell growth and proliferation and induces apoptosis. Statil also enhances adipose-derived stem adipocyte differentiation.
| Cas No. | 72702-95-5 |
|---|---|
| Purity | ≥98% |
| Formula | C17H12BrFN2O3 |
| Formula Wt. | 391.19 |
| IUPAC Name | [3-(4-Bromo-2-fluorobenzyl)-4-oxo-3,4-dihydro-1-phthalazinyl]acetic acid |
| Synonym | Ponalrestat |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | S7601 Info Sheet PDF |
|---|
Pastel E, Pointud JC, Loubeau G, et al. Aldose reductases influence prostaglandin F2α levels and adipocyte differentiation in male mouse and human species. Endocrinology. 2015 May;156(5):1671-84. PMID: 25730106.
Cao Z, Zhou B, Chen X, et al. Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10. Anticancer Drugs. 2014 Sep;25(8):930-7. PMID: 24800887.
El-Kabbani O, Ramsland P, Darmanin C, et al. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme. Proteins. 2003 Feb 1;50(2):230-8. PMID: 12486717.
